About
Galectin-targeting therapeutics
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (11)
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
762
By Phase
PHASE1/PHASE2: 5PHASE2: 3PHASE1: 2
By Status
COMPLETED: 4ACTIVE_NOT_RECRUITING: 2NOT_YET_RECRUITING: 1RECRUITING: 1UNKNOWN: 1WITHDRAWN: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07084584Lead Sponsor
An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
PHASE1/PHASE2Not yet recruiting
184 participants
Started: Jun 10, 2026 · Completed: Oct 10, 2029
NCT05913388Collaborator
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
PHASE2Recruiting
92 participants
Started: Feb 29, 2024 · Completed: Feb 28, 2030
NCT05747573Lead Sponsor
A Study to Compare Pharmacokinetics of GB1211
PHASE1Completed
13 participants
Started: Jan 3, 2023 · Completed: Apr 10, 2023
NCT05240131Lead Sponsor
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
PHASE1/PHASE2Active, not recruiting
88 participants
Started: Mar 15, 2022 · Completed: Nov 1, 2025
NCT05009680Lead Sponsor
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
PHASE1/PHASE2Unknown
54 participants
Started: Sep 9, 2021 · Completed: Jul 4, 2023
Locations (1)
Headquarters
Copenhagen, Denmark
Map
Loading map...